Handbook of Phase II Clinical Trial Design
CRC Press
1st Edition
Published on 26. June 2017
Book
Hardback
352 pages
978-1-4398-2162-6 (ISBN)
Description
In the past, pharmaceutical companies have quickly jumped to Phase III without completion and full analysis of Phase II, which consequently led to failure. In the future, more emphasis needs to be placed on quality designed, conducted, and analyzed Phase II clinical trials. Focusing on Phase II clinical trials conducted in a sequential manner, this handbook presents modern techniques of clinical trial design, describes many Phase II designs, and discusses the software used for sample size and power analysis. It also provides sample size tables for those without the appropriate software to calculate sample size and power and includes numerous real-world examples of trial designs in use.
More details
Series
Language
English
Place of publication
Bosa Roca
United States
Publishing group
Taylor & Francis Inc
Target group
Clinicians (statisticians) involved in biomedical research; students in biostatistics, epidemiology, preventive medicine, and other related fields; pharmaceutical companies and government agencies.
Illustrations
65 s/w Abbildungen
65 Illustrations, black and white
Dimensions
Height: 234 mm
Width: 156 mm
ISBN-13
978-1-4398-2162-6 (9781439821626)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Persons
Yu Shyr is an Ingram Professor of Cancer Research, Professor of Biostatistics, and Director of the Cancer Biostatistics Center at Vanderbilt University School of Medicine.
Lynne D. Berry is an editorial assistant in the Cancer Biostatistics Center at Vanderbilt University School of Medicine.
Lynne D. Berry is an editorial assistant in the Cancer Biostatistics Center at Vanderbilt University School of Medicine.
Author
Vanderbilt University, Nashville, Tennessee, USA
Vanderbilt University, Nashville, Tennessee, USA
Content
Introduction. Single-stage and multiple-stage designs. Adaptive designs: Bayesian and frequentist. Phase II designs for biomarker-based trials. Phase II trial designs for high-dimensional data. Recommendations. Appendix.